Loading...
Market
Which company will be the first to receive FDA approval for a new lung cancer treatment in 2025?
2
Resolution / Starting Odds
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
FDA approval announcements
Story
FDA Approves J&J's Rybrevant for EGFR-Mutated NSCLC, Third New Indication in 2024
Sep 19, 2024, 10:21 PM
The U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with standard care for the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). This approval marks the first targeted regimen to significantly reduce the risk of disease progression by more than half in the second-line setting and is the third new indication for Johnson & Johnson (J&J) in 2024. This development is part of a broader trend of advancements in lung cancer treatment, highlighted at the 2024 IASLC World Conference on Lung Cancer (WCLC24).
View original story
Similar markets
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Yes • 50%
No • 50%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Yes • 50%
No • 50%